Global VLP Vaccines Market

VLP Vaccines Comprehensive Study by Virus (Covid-19, Zika, HIV, Adeno-Associated Virus, Hepatitis C), Form (Tablet, Injectables, Capsules, Others), End Use (Hospitals, Specialty Clinics), Vaccine (Live-Attenuated Vaccines, Inactivated Vaccines, Subunit, Recombinant, Polysaccharide or Conjugate Vaccines, Toxoid Vaccines) Players and Region - Global Market Outlook to 2030

VLP Vaccines Market by XX Submarkets | Forecast Years 2024-2030  

Access Sample Report Make An Enquiry Before Purchase
  • Summary
  • Market Segments
  • Table of Content
  • List of Table & Figures
  • Players Profiled
About VLP Vaccines
Virus-like particles (VLPs) are multiprotein aggregates that resemble the organisation and conformation of genuine viruses but lack the viral genome, potentially resulting in safer and less expensive vaccination options. Virus-like particles look and act like genuine viruses, yet they are not contagious. They have a high potential to elicit a robust immune response without inflicting any actual harm because they do not contain any viral genetic material. VLPs can self-assemble when viral structural proteins like Envelope or Capsid are expressed. Virus-like particles are made up of one or more structural proteins with the capacity to self-assemble when produced in a recombinant form. Single, double, or triple layers of proteins can be formed. A single structural protein forms the basic capsid of the human papillomavirus (HPV) VLPs. SARS Covid, HIV, Adeno-associated virus, and Hepatitis C virus components were used to create VLPs. Bacterial, yeast, insect, and mammalian cells may all be used to make VLPs.

AttributesDetails
Study Period2018-2030
Base Year2023
UnitValue (USD Million)


The companies are exploring the market by adopting mergers & acquisitions, expansions, investments, new service launches and collaborations as their preferred strategies. The players are exploring new geographies through expansions and acquisitions to avail a competitive advantage through combined synergies. Analyst at AMA Research estimates that United States Players will contribute the maximum growth to Global VLP Vaccines market throughout the forecasted period. Established and emerging Players should take a closer view at their existing organizations and reinvent traditional business and operating models to adapt to the future.

GlaxoSmithKline plc (United Kingdom), VLPbio (Spain), Merck KGaA (Germany), Questex LLC. (United States), Fujifilm Holdings Corporation (Japan), SpyBiotech (United Kingdom), VLP Therapeutics. (United States), Serum Institute of India (India), Icosavax, Inc. (United States) and Novavax, Inc. (United States) are some of the key players that are part of study coverage. Additionally, the Players which are also part of the research coverage are Premas Biotech (India), Medicago Inc. (Canada), 3P Bio (Spain), ARTES Biotechnology (Germany) and Others.

Segmentation Overview
AMA Research has segmented the market of Global VLP Vaccines market by and Region.



On the basis of geography, the market of VLP Vaccines has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico). If we see Market by Virus, the sub-segment i.e. Covid-19 will boost the VLP Vaccines market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth. If we see Market by Form, the sub-segment i.e. Tablet will boost the VLP Vaccines market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth. If we see Market by End Use, the sub-segment i.e. Hospitals will boost the VLP Vaccines market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth. If we see Market by Vaccine, the sub-segment i.e. Live-Attenuated Vaccines will boost the VLP Vaccines market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth.

Influencing Trend:
Technical Progress in Medical Industry and High Investments in Research & Development

Market Growth Drivers:
Prevalence of Cancer & Severe Acute Respiratory Syndrome (SARS) Cases, Emergence of Advance and Effective Techniques and Safe and Superior Approach to Plasmid DNA or Viral Vector Treatment

Challenges:
Low Immunogenicity and Fierce Competitive Pressure

Restraints:
Instability Concerns and Side Effects and Allergic Reactions

Opportunities:
Growth in Healthcare infrastructure Due to Pandemic and Regulations in Promoting use of VLP Vaccines

Market Leaders and their expansionary development strategies
In September, 2020 - SpyBiotech and Serum Institute of India (SIIPL) Under their Joint Partnership Announce Completion of Initial Dosage for its Phase I/II trial of a Novel Virus-Like Particle Vaccine Targeting COVID-19. SpyBiotech Had Previously Signed an Exclusive Global Licensing Agreement With SIIPL for its Novel VLP Vaccine.



Key Target Audience
VLP Vaccines Manufactures, New Entrants and Investors, VLP Vaccines Distributors and Suppliers, Venture Capitalists, Government Bodies, Corporate Entities, Government and Private Research Organizations and Others

About Approach
To evaluate and validate the market size various sources including primary and secondary analysis is utilized. AMA Research follows regulatory standards such as NAICS/SIC/ICB/TRCB, to have a better understanding of the market. The market study is conducted on basis of more than 200 companies dealing in the market regional as well as global areas with the purpose to understand the companies positioning regarding the market value, volume, and their market share for regional as well as global.

Further to bring relevance specific to any niche market we set and apply a number of criteria like Geographic Footprints, Regional Segments of Revenue, Operational Centres, etc. The next step is to finalize a team (In-House + Data Agencies) who then starts collecting C & D level executives and profiles, Industry experts, Opinion leaders, etc., and work towards appointment generation.

The primary research is performed by taking the interviews of executives of various companies dealing in the market as well as using the survey reports, research institute, and latest research reports. Meanwhile, the analyst team keeps preparing a set of questionnaires, and after getting the appointee list; the target audience is then tapped and segregated with various mediums and channels that are feasible for making connections that including email communication, telephonic, skype, LinkedIn Group & InMail, Community Forums, Community Forums, open Survey, SurveyMonkey, etc.

Report Objectives / Segmentation Covered

By Virus
  • Covid-19
  • Zika
  • HIV
  • Adeno-Associated Virus
  • Hepatitis C

By Form
  • Tablet
  • Injectables
  • Capsules
  • Others

By End Use
  • Hospitals
  • Specialty Clinics

By Vaccine
  • Live-Attenuated Vaccines
  • Inactivated Vaccines
  • Subunit, Recombinant, Polysaccharide or Conjugate Vaccines
  • Toxoid Vaccines

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Prevalence of Cancer & Severe Acute Respiratory Syndrome (SARS) Cases
      • 3.2.2. Emergence of Advance and Effective Techniques
      • 3.2.3. Safe and Superior Approach to Plasmid DNA or Viral Vector Treatment
    • 3.3. Market Challenges
      • 3.3.1. Low Immunogenicity
      • 3.3.2. Fierce Competitive Pressure
    • 3.4. Market Trends
      • 3.4.1. Technical Progress in Medical Industry
      • 3.4.2. High Investments in Research & Development
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global VLP Vaccines, by Virus, Form, End Use, Vaccine and Region (value and price ) (2018-2023)
    • 5.1. Introduction
    • 5.2. Global VLP Vaccines (Value)
      • 5.2.1. Global VLP Vaccines by: Virus (Value)
        • 5.2.1.1. Covid-19
        • 5.2.1.2. Zika
        • 5.2.1.3. HIV
        • 5.2.1.4. Adeno-Associated Virus
        • 5.2.1.5. Hepatitis C
      • 5.2.2. Global VLP Vaccines by: Form (Value)
        • 5.2.2.1. Tablet
        • 5.2.2.2. Injectables
        • 5.2.2.3. Capsules
        • 5.2.2.4. Others
      • 5.2.3. Global VLP Vaccines by: End Use (Value)
        • 5.2.3.1. Hospitals
        • 5.2.3.2. Specialty Clinics
      • 5.2.4. Global VLP Vaccines by: Vaccine (Value)
        • 5.2.4.1. Live-Attenuated Vaccines
        • 5.2.4.2. Inactivated Vaccines
        • 5.2.4.3. Subunit, Recombinant, Polysaccharide or Conjugate Vaccines
        • 5.2.4.4. Toxoid Vaccines
      • 5.2.5. Global VLP Vaccines Region
        • 5.2.5.1. South America
          • 5.2.5.1.1. Brazil
          • 5.2.5.1.2. Argentina
          • 5.2.5.1.3. Rest of South America
        • 5.2.5.2. Asia Pacific
          • 5.2.5.2.1. China
          • 5.2.5.2.2. Japan
          • 5.2.5.2.3. India
          • 5.2.5.2.4. South Korea
          • 5.2.5.2.5. Australia
          • 5.2.5.2.6. Rest of Asia-Pacific
        • 5.2.5.3. Europe
          • 5.2.5.3.1. Germany
          • 5.2.5.3.2. France
          • 5.2.5.3.3. Italy
          • 5.2.5.3.4. United Kingdom
          • 5.2.5.3.5. Netherlands
          • 5.2.5.3.6. Rest of Europe
        • 5.2.5.4. MEA
          • 5.2.5.4.1. Middle East
          • 5.2.5.4.2. Africa
        • 5.2.5.5. North America
          • 5.2.5.5.1. United States
          • 5.2.5.5.2. Canada
          • 5.2.5.5.3. Mexico
    • 5.3. Global VLP Vaccines (Price)
  • 6. VLP Vaccines: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2023)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. GlaxoSmithKline plc (United Kingdom)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. VLPbio (Spain)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Merck KGaA (Germany)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Questex LLC. (United States)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Fujifilm Holdings Corporation (Japan)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. SpyBiotech (United Kingdom)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. VLP Therapeutics. (United States)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. Serum Institute of India (India)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. Icosavax, Inc. (United States)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
      • 6.4.10. Novavax, Inc. (United States)
        • 6.4.10.1. Business Overview
        • 6.4.10.2. Products/Services Offerings
        • 6.4.10.3. Financial Analysis
        • 6.4.10.4. SWOT Analysis
  • 7. Global VLP Vaccines Sale, by Virus, Form, End Use, Vaccine and Region (value and price ) (2025-2030)
    • 7.1. Introduction
    • 7.2. Global VLP Vaccines (Value)
      • 7.2.1. Global VLP Vaccines by: Virus (Value)
        • 7.2.1.1. Covid-19
        • 7.2.1.2. Zika
        • 7.2.1.3. HIV
        • 7.2.1.4. Adeno-Associated Virus
        • 7.2.1.5. Hepatitis C
      • 7.2.2. Global VLP Vaccines by: Form (Value)
        • 7.2.2.1. Tablet
        • 7.2.2.2. Injectables
        • 7.2.2.3. Capsules
        • 7.2.2.4. Others
      • 7.2.3. Global VLP Vaccines by: End Use (Value)
        • 7.2.3.1. Hospitals
        • 7.2.3.2. Specialty Clinics
      • 7.2.4. Global VLP Vaccines by: Vaccine (Value)
        • 7.2.4.1. Live-Attenuated Vaccines
        • 7.2.4.2. Inactivated Vaccines
        • 7.2.4.3. Subunit, Recombinant, Polysaccharide or Conjugate Vaccines
        • 7.2.4.4. Toxoid Vaccines
      • 7.2.5. Global VLP Vaccines Region
        • 7.2.5.1. South America
          • 7.2.5.1.1. Brazil
          • 7.2.5.1.2. Argentina
          • 7.2.5.1.3. Rest of South America
        • 7.2.5.2. Asia Pacific
          • 7.2.5.2.1. China
          • 7.2.5.2.2. Japan
          • 7.2.5.2.3. India
          • 7.2.5.2.4. South Korea
          • 7.2.5.2.5. Australia
          • 7.2.5.2.6. Rest of Asia-Pacific
        • 7.2.5.3. Europe
          • 7.2.5.3.1. Germany
          • 7.2.5.3.2. France
          • 7.2.5.3.3. Italy
          • 7.2.5.3.4. United Kingdom
          • 7.2.5.3.5. Netherlands
          • 7.2.5.3.6. Rest of Europe
        • 7.2.5.4. MEA
          • 7.2.5.4.1. Middle East
          • 7.2.5.4.2. Africa
        • 7.2.5.5. North America
          • 7.2.5.5.1. United States
          • 7.2.5.5.2. Canada
          • 7.2.5.5.3. Mexico
    • 7.3. Global VLP Vaccines (Price)
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. VLP Vaccines: by Virus(USD Million)
  • Table 2. VLP Vaccines Covid-19 , by Region USD Million (2018-2023)
  • Table 3. VLP Vaccines Zika , by Region USD Million (2018-2023)
  • Table 4. VLP Vaccines HIV , by Region USD Million (2018-2023)
  • Table 5. VLP Vaccines Adeno-Associated Virus , by Region USD Million (2018-2023)
  • Table 6. VLP Vaccines Hepatitis C , by Region USD Million (2018-2023)
  • Table 7. VLP Vaccines: by Form(USD Million)
  • Table 8. VLP Vaccines Tablet , by Region USD Million (2018-2023)
  • Table 9. VLP Vaccines Injectables , by Region USD Million (2018-2023)
  • Table 10. VLP Vaccines Capsules , by Region USD Million (2018-2023)
  • Table 11. VLP Vaccines Others , by Region USD Million (2018-2023)
  • Table 12. VLP Vaccines: by End Use(USD Million)
  • Table 13. VLP Vaccines Hospitals , by Region USD Million (2018-2023)
  • Table 14. VLP Vaccines Specialty Clinics , by Region USD Million (2018-2023)
  • Table 15. VLP Vaccines: by Vaccine(USD Million)
  • Table 16. VLP Vaccines Live-Attenuated Vaccines , by Region USD Million (2018-2023)
  • Table 17. VLP Vaccines Inactivated Vaccines , by Region USD Million (2018-2023)
  • Table 18. VLP Vaccines Subunit, Recombinant, Polysaccharide or Conjugate Vaccines , by Region USD Million (2018-2023)
  • Table 19. VLP Vaccines Toxoid Vaccines , by Region USD Million (2018-2023)
  • Table 20. South America VLP Vaccines, by Country USD Million (2018-2023)
  • Table 21. South America VLP Vaccines, by Virus USD Million (2018-2023)
  • Table 22. South America VLP Vaccines, by Form USD Million (2018-2023)
  • Table 23. South America VLP Vaccines, by End Use USD Million (2018-2023)
  • Table 24. South America VLP Vaccines, by Vaccine USD Million (2018-2023)
  • Table 25. Brazil VLP Vaccines, by Virus USD Million (2018-2023)
  • Table 26. Brazil VLP Vaccines, by Form USD Million (2018-2023)
  • Table 27. Brazil VLP Vaccines, by End Use USD Million (2018-2023)
  • Table 28. Brazil VLP Vaccines, by Vaccine USD Million (2018-2023)
  • Table 29. Argentina VLP Vaccines, by Virus USD Million (2018-2023)
  • Table 30. Argentina VLP Vaccines, by Form USD Million (2018-2023)
  • Table 31. Argentina VLP Vaccines, by End Use USD Million (2018-2023)
  • Table 32. Argentina VLP Vaccines, by Vaccine USD Million (2018-2023)
  • Table 33. Rest of South America VLP Vaccines, by Virus USD Million (2018-2023)
  • Table 34. Rest of South America VLP Vaccines, by Form USD Million (2018-2023)
  • Table 35. Rest of South America VLP Vaccines, by End Use USD Million (2018-2023)
  • Table 36. Rest of South America VLP Vaccines, by Vaccine USD Million (2018-2023)
  • Table 37. Asia Pacific VLP Vaccines, by Country USD Million (2018-2023)
  • Table 38. Asia Pacific VLP Vaccines, by Virus USD Million (2018-2023)
  • Table 39. Asia Pacific VLP Vaccines, by Form USD Million (2018-2023)
  • Table 40. Asia Pacific VLP Vaccines, by End Use USD Million (2018-2023)
  • Table 41. Asia Pacific VLP Vaccines, by Vaccine USD Million (2018-2023)
  • Table 42. China VLP Vaccines, by Virus USD Million (2018-2023)
  • Table 43. China VLP Vaccines, by Form USD Million (2018-2023)
  • Table 44. China VLP Vaccines, by End Use USD Million (2018-2023)
  • Table 45. China VLP Vaccines, by Vaccine USD Million (2018-2023)
  • Table 46. Japan VLP Vaccines, by Virus USD Million (2018-2023)
  • Table 47. Japan VLP Vaccines, by Form USD Million (2018-2023)
  • Table 48. Japan VLP Vaccines, by End Use USD Million (2018-2023)
  • Table 49. Japan VLP Vaccines, by Vaccine USD Million (2018-2023)
  • Table 50. India VLP Vaccines, by Virus USD Million (2018-2023)
  • Table 51. India VLP Vaccines, by Form USD Million (2018-2023)
  • Table 52. India VLP Vaccines, by End Use USD Million (2018-2023)
  • Table 53. India VLP Vaccines, by Vaccine USD Million (2018-2023)
  • Table 54. South Korea VLP Vaccines, by Virus USD Million (2018-2023)
  • Table 55. South Korea VLP Vaccines, by Form USD Million (2018-2023)
  • Table 56. South Korea VLP Vaccines, by End Use USD Million (2018-2023)
  • Table 57. South Korea VLP Vaccines, by Vaccine USD Million (2018-2023)
  • Table 58. Australia VLP Vaccines, by Virus USD Million (2018-2023)
  • Table 59. Australia VLP Vaccines, by Form USD Million (2018-2023)
  • Table 60. Australia VLP Vaccines, by End Use USD Million (2018-2023)
  • Table 61. Australia VLP Vaccines, by Vaccine USD Million (2018-2023)
  • Table 62. Rest of Asia-Pacific VLP Vaccines, by Virus USD Million (2018-2023)
  • Table 63. Rest of Asia-Pacific VLP Vaccines, by Form USD Million (2018-2023)
  • Table 64. Rest of Asia-Pacific VLP Vaccines, by End Use USD Million (2018-2023)
  • Table 65. Rest of Asia-Pacific VLP Vaccines, by Vaccine USD Million (2018-2023)
  • Table 66. Europe VLP Vaccines, by Country USD Million (2018-2023)
  • Table 67. Europe VLP Vaccines, by Virus USD Million (2018-2023)
  • Table 68. Europe VLP Vaccines, by Form USD Million (2018-2023)
  • Table 69. Europe VLP Vaccines, by End Use USD Million (2018-2023)
  • Table 70. Europe VLP Vaccines, by Vaccine USD Million (2018-2023)
  • Table 71. Germany VLP Vaccines, by Virus USD Million (2018-2023)
  • Table 72. Germany VLP Vaccines, by Form USD Million (2018-2023)
  • Table 73. Germany VLP Vaccines, by End Use USD Million (2018-2023)
  • Table 74. Germany VLP Vaccines, by Vaccine USD Million (2018-2023)
  • Table 75. France VLP Vaccines, by Virus USD Million (2018-2023)
  • Table 76. France VLP Vaccines, by Form USD Million (2018-2023)
  • Table 77. France VLP Vaccines, by End Use USD Million (2018-2023)
  • Table 78. France VLP Vaccines, by Vaccine USD Million (2018-2023)
  • Table 79. Italy VLP Vaccines, by Virus USD Million (2018-2023)
  • Table 80. Italy VLP Vaccines, by Form USD Million (2018-2023)
  • Table 81. Italy VLP Vaccines, by End Use USD Million (2018-2023)
  • Table 82. Italy VLP Vaccines, by Vaccine USD Million (2018-2023)
  • Table 83. United Kingdom VLP Vaccines, by Virus USD Million (2018-2023)
  • Table 84. United Kingdom VLP Vaccines, by Form USD Million (2018-2023)
  • Table 85. United Kingdom VLP Vaccines, by End Use USD Million (2018-2023)
  • Table 86. United Kingdom VLP Vaccines, by Vaccine USD Million (2018-2023)
  • Table 87. Netherlands VLP Vaccines, by Virus USD Million (2018-2023)
  • Table 88. Netherlands VLP Vaccines, by Form USD Million (2018-2023)
  • Table 89. Netherlands VLP Vaccines, by End Use USD Million (2018-2023)
  • Table 90. Netherlands VLP Vaccines, by Vaccine USD Million (2018-2023)
  • Table 91. Rest of Europe VLP Vaccines, by Virus USD Million (2018-2023)
  • Table 92. Rest of Europe VLP Vaccines, by Form USD Million (2018-2023)
  • Table 93. Rest of Europe VLP Vaccines, by End Use USD Million (2018-2023)
  • Table 94. Rest of Europe VLP Vaccines, by Vaccine USD Million (2018-2023)
  • Table 95. MEA VLP Vaccines, by Country USD Million (2018-2023)
  • Table 96. MEA VLP Vaccines, by Virus USD Million (2018-2023)
  • Table 97. MEA VLP Vaccines, by Form USD Million (2018-2023)
  • Table 98. MEA VLP Vaccines, by End Use USD Million (2018-2023)
  • Table 99. MEA VLP Vaccines, by Vaccine USD Million (2018-2023)
  • Table 100. Middle East VLP Vaccines, by Virus USD Million (2018-2023)
  • Table 101. Middle East VLP Vaccines, by Form USD Million (2018-2023)
  • Table 102. Middle East VLP Vaccines, by End Use USD Million (2018-2023)
  • Table 103. Middle East VLP Vaccines, by Vaccine USD Million (2018-2023)
  • Table 104. Africa VLP Vaccines, by Virus USD Million (2018-2023)
  • Table 105. Africa VLP Vaccines, by Form USD Million (2018-2023)
  • Table 106. Africa VLP Vaccines, by End Use USD Million (2018-2023)
  • Table 107. Africa VLP Vaccines, by Vaccine USD Million (2018-2023)
  • Table 108. North America VLP Vaccines, by Country USD Million (2018-2023)
  • Table 109. North America VLP Vaccines, by Virus USD Million (2018-2023)
  • Table 110. North America VLP Vaccines, by Form USD Million (2018-2023)
  • Table 111. North America VLP Vaccines, by End Use USD Million (2018-2023)
  • Table 112. North America VLP Vaccines, by Vaccine USD Million (2018-2023)
  • Table 113. United States VLP Vaccines, by Virus USD Million (2018-2023)
  • Table 114. United States VLP Vaccines, by Form USD Million (2018-2023)
  • Table 115. United States VLP Vaccines, by End Use USD Million (2018-2023)
  • Table 116. United States VLP Vaccines, by Vaccine USD Million (2018-2023)
  • Table 117. Canada VLP Vaccines, by Virus USD Million (2018-2023)
  • Table 118. Canada VLP Vaccines, by Form USD Million (2018-2023)
  • Table 119. Canada VLP Vaccines, by End Use USD Million (2018-2023)
  • Table 120. Canada VLP Vaccines, by Vaccine USD Million (2018-2023)
  • Table 121. Mexico VLP Vaccines, by Virus USD Million (2018-2023)
  • Table 122. Mexico VLP Vaccines, by Form USD Million (2018-2023)
  • Table 123. Mexico VLP Vaccines, by End Use USD Million (2018-2023)
  • Table 124. Mexico VLP Vaccines, by Vaccine USD Million (2018-2023)
  • Table 125. Company Basic Information, Sales Area and Its Competitors
  • Table 126. Company Basic Information, Sales Area and Its Competitors
  • Table 127. Company Basic Information, Sales Area and Its Competitors
  • Table 128. Company Basic Information, Sales Area and Its Competitors
  • Table 129. Company Basic Information, Sales Area and Its Competitors
  • Table 130. Company Basic Information, Sales Area and Its Competitors
  • Table 131. Company Basic Information, Sales Area and Its Competitors
  • Table 132. Company Basic Information, Sales Area and Its Competitors
  • Table 133. Company Basic Information, Sales Area and Its Competitors
  • Table 134. Company Basic Information, Sales Area and Its Competitors
  • Table 135. VLP Vaccines: by Virus(USD Million)
  • Table 136. VLP Vaccines Covid-19 , by Region USD Million (2025-2030)
  • Table 137. VLP Vaccines Zika , by Region USD Million (2025-2030)
  • Table 138. VLP Vaccines HIV , by Region USD Million (2025-2030)
  • Table 139. VLP Vaccines Adeno-Associated Virus , by Region USD Million (2025-2030)
  • Table 140. VLP Vaccines Hepatitis C , by Region USD Million (2025-2030)
  • Table 141. VLP Vaccines: by Form(USD Million)
  • Table 142. VLP Vaccines Tablet , by Region USD Million (2025-2030)
  • Table 143. VLP Vaccines Injectables , by Region USD Million (2025-2030)
  • Table 144. VLP Vaccines Capsules , by Region USD Million (2025-2030)
  • Table 145. VLP Vaccines Others , by Region USD Million (2025-2030)
  • Table 146. VLP Vaccines: by End Use(USD Million)
  • Table 147. VLP Vaccines Hospitals , by Region USD Million (2025-2030)
  • Table 148. VLP Vaccines Specialty Clinics , by Region USD Million (2025-2030)
  • Table 149. VLP Vaccines: by Vaccine(USD Million)
  • Table 150. VLP Vaccines Live-Attenuated Vaccines , by Region USD Million (2025-2030)
  • Table 151. VLP Vaccines Inactivated Vaccines , by Region USD Million (2025-2030)
  • Table 152. VLP Vaccines Subunit, Recombinant, Polysaccharide or Conjugate Vaccines , by Region USD Million (2025-2030)
  • Table 153. VLP Vaccines Toxoid Vaccines , by Region USD Million (2025-2030)
  • Table 154. South America VLP Vaccines, by Country USD Million (2025-2030)
  • Table 155. South America VLP Vaccines, by Virus USD Million (2025-2030)
  • Table 156. South America VLP Vaccines, by Form USD Million (2025-2030)
  • Table 157. South America VLP Vaccines, by End Use USD Million (2025-2030)
  • Table 158. South America VLP Vaccines, by Vaccine USD Million (2025-2030)
  • Table 159. Brazil VLP Vaccines, by Virus USD Million (2025-2030)
  • Table 160. Brazil VLP Vaccines, by Form USD Million (2025-2030)
  • Table 161. Brazil VLP Vaccines, by End Use USD Million (2025-2030)
  • Table 162. Brazil VLP Vaccines, by Vaccine USD Million (2025-2030)
  • Table 163. Argentina VLP Vaccines, by Virus USD Million (2025-2030)
  • Table 164. Argentina VLP Vaccines, by Form USD Million (2025-2030)
  • Table 165. Argentina VLP Vaccines, by End Use USD Million (2025-2030)
  • Table 166. Argentina VLP Vaccines, by Vaccine USD Million (2025-2030)
  • Table 167. Rest of South America VLP Vaccines, by Virus USD Million (2025-2030)
  • Table 168. Rest of South America VLP Vaccines, by Form USD Million (2025-2030)
  • Table 169. Rest of South America VLP Vaccines, by End Use USD Million (2025-2030)
  • Table 170. Rest of South America VLP Vaccines, by Vaccine USD Million (2025-2030)
  • Table 171. Asia Pacific VLP Vaccines, by Country USD Million (2025-2030)
  • Table 172. Asia Pacific VLP Vaccines, by Virus USD Million (2025-2030)
  • Table 173. Asia Pacific VLP Vaccines, by Form USD Million (2025-2030)
  • Table 174. Asia Pacific VLP Vaccines, by End Use USD Million (2025-2030)
  • Table 175. Asia Pacific VLP Vaccines, by Vaccine USD Million (2025-2030)
  • Table 176. China VLP Vaccines, by Virus USD Million (2025-2030)
  • Table 177. China VLP Vaccines, by Form USD Million (2025-2030)
  • Table 178. China VLP Vaccines, by End Use USD Million (2025-2030)
  • Table 179. China VLP Vaccines, by Vaccine USD Million (2025-2030)
  • Table 180. Japan VLP Vaccines, by Virus USD Million (2025-2030)
  • Table 181. Japan VLP Vaccines, by Form USD Million (2025-2030)
  • Table 182. Japan VLP Vaccines, by End Use USD Million (2025-2030)
  • Table 183. Japan VLP Vaccines, by Vaccine USD Million (2025-2030)
  • Table 184. India VLP Vaccines, by Virus USD Million (2025-2030)
  • Table 185. India VLP Vaccines, by Form USD Million (2025-2030)
  • Table 186. India VLP Vaccines, by End Use USD Million (2025-2030)
  • Table 187. India VLP Vaccines, by Vaccine USD Million (2025-2030)
  • Table 188. South Korea VLP Vaccines, by Virus USD Million (2025-2030)
  • Table 189. South Korea VLP Vaccines, by Form USD Million (2025-2030)
  • Table 190. South Korea VLP Vaccines, by End Use USD Million (2025-2030)
  • Table 191. South Korea VLP Vaccines, by Vaccine USD Million (2025-2030)
  • Table 192. Australia VLP Vaccines, by Virus USD Million (2025-2030)
  • Table 193. Australia VLP Vaccines, by Form USD Million (2025-2030)
  • Table 194. Australia VLP Vaccines, by End Use USD Million (2025-2030)
  • Table 195. Australia VLP Vaccines, by Vaccine USD Million (2025-2030)
  • Table 196. Rest of Asia-Pacific VLP Vaccines, by Virus USD Million (2025-2030)
  • Table 197. Rest of Asia-Pacific VLP Vaccines, by Form USD Million (2025-2030)
  • Table 198. Rest of Asia-Pacific VLP Vaccines, by End Use USD Million (2025-2030)
  • Table 199. Rest of Asia-Pacific VLP Vaccines, by Vaccine USD Million (2025-2030)
  • Table 200. Europe VLP Vaccines, by Country USD Million (2025-2030)
  • Table 201. Europe VLP Vaccines, by Virus USD Million (2025-2030)
  • Table 202. Europe VLP Vaccines, by Form USD Million (2025-2030)
  • Table 203. Europe VLP Vaccines, by End Use USD Million (2025-2030)
  • Table 204. Europe VLP Vaccines, by Vaccine USD Million (2025-2030)
  • Table 205. Germany VLP Vaccines, by Virus USD Million (2025-2030)
  • Table 206. Germany VLP Vaccines, by Form USD Million (2025-2030)
  • Table 207. Germany VLP Vaccines, by End Use USD Million (2025-2030)
  • Table 208. Germany VLP Vaccines, by Vaccine USD Million (2025-2030)
  • Table 209. France VLP Vaccines, by Virus USD Million (2025-2030)
  • Table 210. France VLP Vaccines, by Form USD Million (2025-2030)
  • Table 211. France VLP Vaccines, by End Use USD Million (2025-2030)
  • Table 212. France VLP Vaccines, by Vaccine USD Million (2025-2030)
  • Table 213. Italy VLP Vaccines, by Virus USD Million (2025-2030)
  • Table 214. Italy VLP Vaccines, by Form USD Million (2025-2030)
  • Table 215. Italy VLP Vaccines, by End Use USD Million (2025-2030)
  • Table 216. Italy VLP Vaccines, by Vaccine USD Million (2025-2030)
  • Table 217. United Kingdom VLP Vaccines, by Virus USD Million (2025-2030)
  • Table 218. United Kingdom VLP Vaccines, by Form USD Million (2025-2030)
  • Table 219. United Kingdom VLP Vaccines, by End Use USD Million (2025-2030)
  • Table 220. United Kingdom VLP Vaccines, by Vaccine USD Million (2025-2030)
  • Table 221. Netherlands VLP Vaccines, by Virus USD Million (2025-2030)
  • Table 222. Netherlands VLP Vaccines, by Form USD Million (2025-2030)
  • Table 223. Netherlands VLP Vaccines, by End Use USD Million (2025-2030)
  • Table 224. Netherlands VLP Vaccines, by Vaccine USD Million (2025-2030)
  • Table 225. Rest of Europe VLP Vaccines, by Virus USD Million (2025-2030)
  • Table 226. Rest of Europe VLP Vaccines, by Form USD Million (2025-2030)
  • Table 227. Rest of Europe VLP Vaccines, by End Use USD Million (2025-2030)
  • Table 228. Rest of Europe VLP Vaccines, by Vaccine USD Million (2025-2030)
  • Table 229. MEA VLP Vaccines, by Country USD Million (2025-2030)
  • Table 230. MEA VLP Vaccines, by Virus USD Million (2025-2030)
  • Table 231. MEA VLP Vaccines, by Form USD Million (2025-2030)
  • Table 232. MEA VLP Vaccines, by End Use USD Million (2025-2030)
  • Table 233. MEA VLP Vaccines, by Vaccine USD Million (2025-2030)
  • Table 234. Middle East VLP Vaccines, by Virus USD Million (2025-2030)
  • Table 235. Middle East VLP Vaccines, by Form USD Million (2025-2030)
  • Table 236. Middle East VLP Vaccines, by End Use USD Million (2025-2030)
  • Table 237. Middle East VLP Vaccines, by Vaccine USD Million (2025-2030)
  • Table 238. Africa VLP Vaccines, by Virus USD Million (2025-2030)
  • Table 239. Africa VLP Vaccines, by Form USD Million (2025-2030)
  • Table 240. Africa VLP Vaccines, by End Use USD Million (2025-2030)
  • Table 241. Africa VLP Vaccines, by Vaccine USD Million (2025-2030)
  • Table 242. North America VLP Vaccines, by Country USD Million (2025-2030)
  • Table 243. North America VLP Vaccines, by Virus USD Million (2025-2030)
  • Table 244. North America VLP Vaccines, by Form USD Million (2025-2030)
  • Table 245. North America VLP Vaccines, by End Use USD Million (2025-2030)
  • Table 246. North America VLP Vaccines, by Vaccine USD Million (2025-2030)
  • Table 247. United States VLP Vaccines, by Virus USD Million (2025-2030)
  • Table 248. United States VLP Vaccines, by Form USD Million (2025-2030)
  • Table 249. United States VLP Vaccines, by End Use USD Million (2025-2030)
  • Table 250. United States VLP Vaccines, by Vaccine USD Million (2025-2030)
  • Table 251. Canada VLP Vaccines, by Virus USD Million (2025-2030)
  • Table 252. Canada VLP Vaccines, by Form USD Million (2025-2030)
  • Table 253. Canada VLP Vaccines, by End Use USD Million (2025-2030)
  • Table 254. Canada VLP Vaccines, by Vaccine USD Million (2025-2030)
  • Table 255. Mexico VLP Vaccines, by Virus USD Million (2025-2030)
  • Table 256. Mexico VLP Vaccines, by Form USD Million (2025-2030)
  • Table 257. Mexico VLP Vaccines, by End Use USD Million (2025-2030)
  • Table 258. Mexico VLP Vaccines, by Vaccine USD Million (2025-2030)
  • Table 259. Research Programs/Design for This Report
  • Table 260. Key Data Information from Secondary Sources
  • Table 261. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global VLP Vaccines: by Virus USD Million (2018-2023)
  • Figure 5. Global VLP Vaccines: by Form USD Million (2018-2023)
  • Figure 6. Global VLP Vaccines: by End Use USD Million (2018-2023)
  • Figure 7. Global VLP Vaccines: by Vaccine USD Million (2018-2023)
  • Figure 8. South America VLP Vaccines Share (%), by Country
  • Figure 9. Asia Pacific VLP Vaccines Share (%), by Country
  • Figure 10. Europe VLP Vaccines Share (%), by Country
  • Figure 11. MEA VLP Vaccines Share (%), by Country
  • Figure 12. North America VLP Vaccines Share (%), by Country
  • Figure 13. Global VLP Vaccines share by Players 2023 (%)
  • Figure 14. Global VLP Vaccines share by Players (Top 3) 2023(%)
  • Figure 15. Global VLP Vaccines share by Players (Top 5) 2023(%)
  • Figure 16. BCG Matrix for key Companies
  • Figure 17. GlaxoSmithKline plc (United Kingdom) Revenue, Net Income and Gross profit
  • Figure 18. GlaxoSmithKline plc (United Kingdom) Revenue: by Geography 2023
  • Figure 19. VLPbio (Spain) Revenue, Net Income and Gross profit
  • Figure 20. VLPbio (Spain) Revenue: by Geography 2023
  • Figure 21. Merck KGaA (Germany) Revenue, Net Income and Gross profit
  • Figure 22. Merck KGaA (Germany) Revenue: by Geography 2023
  • Figure 23. Questex LLC. (United States) Revenue, Net Income and Gross profit
  • Figure 24. Questex LLC. (United States) Revenue: by Geography 2023
  • Figure 25. Fujifilm Holdings Corporation (Japan) Revenue, Net Income and Gross profit
  • Figure 26. Fujifilm Holdings Corporation (Japan) Revenue: by Geography 2023
  • Figure 27. SpyBiotech (United Kingdom) Revenue, Net Income and Gross profit
  • Figure 28. SpyBiotech (United Kingdom) Revenue: by Geography 2023
  • Figure 29. VLP Therapeutics. (United States) Revenue, Net Income and Gross profit
  • Figure 30. VLP Therapeutics. (United States) Revenue: by Geography 2023
  • Figure 31. Serum Institute of India (India) Revenue, Net Income and Gross profit
  • Figure 32. Serum Institute of India (India) Revenue: by Geography 2023
  • Figure 33. Icosavax, Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 34. Icosavax, Inc. (United States) Revenue: by Geography 2023
  • Figure 35. Novavax, Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 36. Novavax, Inc. (United States) Revenue: by Geography 2023
  • Figure 37. Global VLP Vaccines: by Virus USD Million (2025-2030)
  • Figure 38. Global VLP Vaccines: by Form USD Million (2025-2030)
  • Figure 39. Global VLP Vaccines: by End Use USD Million (2025-2030)
  • Figure 40. Global VLP Vaccines: by Vaccine USD Million (2025-2030)
  • Figure 41. South America VLP Vaccines Share (%), by Country
  • Figure 42. Asia Pacific VLP Vaccines Share (%), by Country
  • Figure 43. Europe VLP Vaccines Share (%), by Country
  • Figure 44. MEA VLP Vaccines Share (%), by Country
  • Figure 45. North America VLP Vaccines Share (%), by Country
List of companies from research coverage that are profiled in the study
  • GlaxoSmithKline plc (United Kingdom)
  • VLPbio (Spain)
  • Merck KGaA (Germany)
  • Questex LLC. (United States)
  • Fujifilm Holdings Corporation (Japan)
  • SpyBiotech (United Kingdom)
  • VLP Therapeutics. (United States)
  • Serum Institute of India (India)
  • Icosavax, Inc. (United States)
  • Novavax, Inc. (United States)
Additional players considered in the study are as follows:
Premas Biotech (India) , Medicago Inc. (Canada) , 3P Bio (Spain) , ARTES Biotechnology (Germany) , Others
Select User Access Type

Key Highlights of Report


Apr 2024 224 Pages 52 Tables Base Year: 2023 Coverage: 15+ Companies; 18 Countries

Request Sample Pages

Budget constraints? Get in touch with us for special pricing


Check Discount Now
Global VLP Vaccines Market Quantitative research analysis
Global VLP Vaccines Market Qualitative Industry Analysis
DOWNLOAD SAMPLE PDF

Talk to Our Experts

Want to Customize Study?


"We employ Market statistics, Industry benchmarking, Patent analysis, and Technological Insights to derive requirements and provide customize scope of work."

Make an Enquiry Now

Frequently Asked Questions (FAQ):

The standard version of the report profiles players such as GlaxoSmithKline plc (United Kingdom), VLPbio (Spain), Merck KGaA (Germany), Questex LLC. (United States), Fujifilm Holdings Corporation (Japan), SpyBiotech (United Kingdom), VLP Therapeutics. (United States), Serum Institute of India (India), Icosavax, Inc. (United States) and Novavax, Inc. (United States) etc.
The Study can be customized subject to feasibility and data availability. Please connect with our sales representative for further information.
"Technical Progress in Medical Industry " is seen as one of major influencing trends for VLP Vaccines Market during projected period 2023-2030.
The VLP Vaccines market study includes a random mix of players, including both market leaders and some top growing emerging players. Connect with our sales executive to get a complete company list in our research coverage.

Know More About Global VLP Vaccines Market Report?

Have a Query? Click Here

Other Related Reports

Antithyroid Drug Comprehensive Study by Type (Propylthiouracil, Methimazole), Application (Hospital, Specialty Clinics), Distribution Channels (Hospital Dispensary, Retail Pharmacy, Online Pharmacy) ...
$ 3500
Yacon Syrup Comprehensive Study by Type (Conventional, Organic), Application (Household, Commercial), Packaging (Bottle, Can, Pouches, Others), Sales Channel (Online, Offline) Players and Region - Gl...
$ 3500
Nasal Antiseptics Comprehensive Study by Type (Lactoperoxidase, Lactoferrin, Interferons, Povidone- Iodine, Alcohols, Others), Application (Hospitals, Laboratories, Clinics, Others), Sales Channel (O...
$ 3500
Aflibercept Drug Comprehensive Study by Application (Diabetic Macular Edoema (DME), Age-Related Macular Degeneration (AMD), Central Retinal Vein Occlusion (CRVO)), Distribution (Hospital Dispensary, ...
$ 3650
Pharmaceutical Lactose Comprehensive Study by Type (Crystalline Monohydrate Lactose, Inhalation Lactose, Granulated Lactose, Spray Dried Lactose, Others), Application (Tablets Manufacturing, Capsule ...
$ 3350
Flu RNA Vaccines Comprehensive Study by Application (Hospitals, Emergency Departments, Clinics, Others), End Users (Adults, Kids), Sales (Hospitals, Retail Pharmacy Stores), Usages (Infectious Diseas...
$ 3500